SE8801275L - New uses of dopamine agonists - Google Patents

New uses of dopamine agonists

Info

Publication number
SE8801275L
SE8801275L SE8801275A SE8801275A SE8801275L SE 8801275 L SE8801275 L SE 8801275L SE 8801275 A SE8801275 A SE 8801275A SE 8801275 A SE8801275 A SE 8801275A SE 8801275 L SE8801275 L SE 8801275L
Authority
SE
Sweden
Prior art keywords
dopamine agonists
new uses
dopamine
schizophrenia
anxiety
Prior art date
Application number
SE8801275A
Other languages
Unknown language ( )
English (en)
Other versions
SE8801275D0 (sv
SE8801275A0 (sv
Inventor
R Markstein
J Palacios
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878708626A external-priority patent/GB8708626D0/en
Priority claimed from GB878708898A external-priority patent/GB8708898D0/en
Priority claimed from GB878710062A external-priority patent/GB8710062D0/en
Priority claimed from GB878720366A external-priority patent/GB8720366D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of SE8801275D0 publication Critical patent/SE8801275D0/sv
Publication of SE8801275A0 publication Critical patent/SE8801275A0/sv
Publication of SE8801275L publication Critical patent/SE8801275L/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, ***e
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE8801275A 1987-04-10 1988-04-08 New uses of dopamine agonists SE8801275L (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878708626A GB8708626D0 (en) 1987-04-10 1987-04-10 Indolophenanthridines
GB878708898A GB8708898D0 (en) 1987-04-14 1987-04-14 Indolophenanthridines
GB878710062A GB8710062D0 (en) 1987-04-28 1987-04-28 Indolophenanthridines
GB878720366A GB8720366D0 (en) 1987-08-28 1987-08-28 Dopamine d1 receptor agonists

Publications (3)

Publication Number Publication Date
SE8801275D0 SE8801275D0 (sv) 1988-04-08
SE8801275A0 SE8801275A0 (sv) 1988-10-19
SE8801275L true SE8801275L (sv) 1988-10-19

Family

ID=27449909

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8801275A SE8801275L (sv) 1987-04-10 1988-04-08 New uses of dopamine agonists

Country Status (11)

Country Link
US (1) US4855306A (sv)
JP (1) JPS63258819A (sv)
KR (1) KR880012227A (sv)
AU (1) AU1440088A (sv)
DE (1) DE3811274A1 (sv)
DK (1) DK193588A (sv)
FR (1) FR2613623A1 (sv)
GB (1) GB2205495A (sv)
IT (1) IT1219906B (sv)
NL (1) NL8800823A (sv)
SE (1) SE8801275L (sv)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006794B1 (en) * 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
US20040058873A1 (en) * 1998-03-12 2004-03-25 Esmond Robert W. Method for treating or preventing Alzheimer's disease
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
DE10148233A1 (de) * 2001-09-28 2003-04-10 Boehringer Ingelheim Pharma Verbindungen zur Reduzierung übermäßiger Nahrungsaufnahme
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
CN1320886C (zh) * 2002-05-17 2007-06-13 杜克大学 安非他酮与抗惊厥药在制备治疗肥胖症的药物的用途
US20040266794A1 (en) * 2003-03-21 2004-12-30 Boehringer Ingelheim International Gmbh Pramipexole for the reduction of excessive food intake for children
DE10312809A1 (de) * 2003-03-21 2004-09-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pramipexol zur Reduzierung übermäßiger Nahrungsaufnahme bei Kindern
JP4343948B2 (ja) * 2003-04-29 2009-10-14 オレキシジェン・セラピューティクス・インコーポレーテッド 体重減少に影響を及ぼすための組成物
EP1626703A2 (en) * 2003-05-22 2006-02-22 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007517901A (ja) * 2004-01-13 2007-07-05 デューク・ユニバーシティー 体重の減少に作用する鎮痙剤及び抗精神病剤の組成物
CN1968692A (zh) * 2004-05-03 2007-05-23 杜克大学 影响体重减轻的组合物
WO2006119353A2 (en) * 2005-05-03 2006-11-09 University Of South Carolina Dopamine receptor agonists in the treatment and prevention of hiv-induced dementia
CA2630624C (en) 2005-11-22 2013-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
KR20160072276A (ko) 2006-11-09 2016-06-22 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CA2750903C (en) * 2009-08-27 2015-08-11 Daikin Industries, Ltd. Processing additive, molding composition, masterbatch of processing additive and molding article
CN102724878A (zh) 2010-01-11 2012-10-10 奥雷西根治疗公司 在重度抑郁症患者中提供体重减轻疗法的方法
EA201492175A1 (ru) 2012-06-06 2015-10-30 Орексиджен Терапьютикс, Инк. Способы лечения избыточного веса и ожирения

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3402392A1 (de) * 1984-01-25 1985-08-01 Sandoz-Patent-GmbH, 7850 Lörrach Neue ergolinderivate, deren herstellung und deren verwendung

Also Published As

Publication number Publication date
US4855306A (en) 1989-08-08
GB2205495A (en) 1988-12-14
SE8801275D0 (sv) 1988-04-08
IT8847814A0 (it) 1988-04-05
FR2613623A1 (fr) 1988-10-14
DK193588D0 (da) 1988-04-08
GB8808125D0 (en) 1988-05-11
AU1440088A (en) 1988-10-13
SE8801275A0 (sv) 1988-10-19
NL8800823A (nl) 1988-11-01
DE3811274A1 (de) 1988-10-27
KR880012227A (ko) 1988-11-26
JPS63258819A (ja) 1988-10-26
DK193588A (da) 1988-10-11
IT1219906B (it) 1990-05-24

Similar Documents

Publication Publication Date Title
SE8801275L (sv) New uses of dopamine agonists
PT804196E (pt) Utilizacao de antagonistas de serotonina (5ht3) para o tratamento de fibromialgia
EP0438230A3 (en) Indole-substituted five-membered heteroaromatic compounds
SE8203966L (sv) Kirurgiskt instrument for utforande av anastomos med hjelp av ringformiga festelement samt festelement for utforande av anastomos
IL98163A0 (en) Isoxazole-4-carboxamides and hydroxyalkylidene-cyanoacetamides,pharmaceuticals containing these compounds and their use
DE69110309D1 (de) Vorrichtung zur Erkennung einer baldigen Erschöpfung des Tintenvorrates.
DK182786A (da) Ikke-lagdelt toerformet absorberende produkt og fremgangsmaade til fremstilling af produktet
NO960630L (no) Heterocykler anvendelige som neurokinin antagonister
DE69008877T2 (de) Quervorrichtung zur Zuführung von Dampf.
ES529313A0 (es) Procedimiento para la preparacion de 3-(1-sustituido-4-piperidil)-1, 2-bencisoxazoles
DE3884689D1 (de) Vorrichtung zum Durchströmen von Dampf.
YU43809B (en) Process for obtaining new substituted benzamides
DK83789D0 (da) Substituerede 1,2,4-triazindioner, fremgangsmaader og mellemprodukter til deres fremstilling samt deres anvendelse
ES524439A0 (es) Procedimiento de obtencion de los 2-amino 5- (aralcoil piperidino alcoil) amino 1,4-diazoles
ES2039211T3 (es) Nuevos n-glicosilamidoderivados, procedimientos para su obtencion y su empleo como medicamentos.
DE58906414D1 (de) Vorrichtung zur Begrenzung des Eingangsstromes eines Speisegerätes.
DE59003199D1 (de) Vorrichtung zur Aufnahme von Notschlüsseln.
DE3761148D1 (de) Vorrichtung zum ausgleich der schienenschatten an erhitzen brammen.
DE59000366D1 (de) Vorrichtung zum regeln des betriebs von hydromotoren.
DE69004417T2 (de) Oral verabreichte porphyrine zur regelung der eisenabsorption.
ES2040362T3 (es) Procedimiento para la preparacion de 2-(benzhidrilsulfonil)acetamida.
ES1012648U (es) Agarradero para baneras.
IT8985508A0 (it) Dispositivo per allargare pelli o simili.
SE8902700D0 (sv) Stoedkrage
ATE79937T1 (de) Vorrichtung zum absperren von rohrleitungen.

Legal Events

Date Code Title Description
NAV Patent application has lapsed

Ref document number: 8801275-2

Effective date: 19911101

Format of ref document f/p: F